Exciting Developments in Alzheimer’s Research!

A new study presented at the AAIC suggests that Novo’s GLP-1 drug liraglutide, known for treating diabetes and obesity, may also slow cognitive decline in Alzheimer’s disease. The study found significant brain-protective effects, with nearly 50% less brain volume loss in key regions. Although further research is needed, this could be a promising step forward in the fight against Alzheimer’s.

At Akshar Global Clinical Research, we are closely following these advancements that have the potential to change lives.